Inhibikase Therapeutics, Inc. (IKT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.83 |
| Open | 1.83 |
| Day High | 1.88 |
| Day Low | 1.79 |
| 52-Week High | 2.26 |
| 52-Week Low | 1.33 |
| Volume | 330,913.34 |
| Average Volume | 899,090 |
| Market Cap | 242.28M |
| PE | -4.17 |
| EPS | -0.44 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 1.7 |
| Change | 0.01 |
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 21, 2025 2:54 AM GMT
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“P
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Nov 20, 2025 9:12 PM GMT
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
GlobeNewswire Inc.
Nov 20, 2025 9:01 PM GMT
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibik